The effect of different immunosuppressive regimens on TGF-β1 expression in kidney transplant patients

Transplant International

Volumn 18, Issue 6, 2005, Pages 668-671

  Matl, Ivo ^a   Viklický, Ondřej ^a   Voska, Luděk ^a   Lodererové, Alena ^a   Vítko, Štefan ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Chronic allograft nephropathy; Cyclosporin A; Protocol biopsy; Tacrolimus; Transforming growth factor 1

Indexed keywords

CYCLOSPORIN A; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA1; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; TGFB1 PROTEIN, HUMAN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CHRONIC ALLOGRAFT NEPHROPATHY; DIASTOLIC BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY GRAFT; KIDNEY STRUCTURE; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ALLOTRANSPLANTATION; BIOPSY; CHEMISTRY; KIDNEY; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; BIOPSY; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSPLANTATION, HOMOLOGOUS;

EID: 23244467142     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2005.00115.x     Document Type: Article

References (16)

1. Furness PN. Histopathology of chronic renal allograft dysfunction. Transplantation 2001; 71: SS31.
2. Tullius SG, Tilney NL. Both alloantigen-dependent and independent factors influence chronic allograft rejection. Transplantation 1995; 59: 313.
3. Khanna A, Li B, Sharma VK, Suthanthiran M. Immunoregulatory and fibrogenic activities of cyclosporine: a unifying hypothesis based on transforming growth factor-β expression. Transplant Proc 1996; 28: 2015.
4. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
5. Horvath LZ, Friess H, Schilling M, et al. Altered expression of transforming growth factor-β in chronic renal rejection. Kidney Int 1996; 50: 489.
6. Rush D, Nickers P, Jeffery J. Protocol biopsies in renal transplantation: research tool or clinically useful? Curr Opin Nephrol Hypertens 1998; 7: 691.
7. Legendre C, Thervet E, Skhiri H, et al. Histologic features of chronic allograft nephropathy revealed by protocol biopsies in kidney transplant recipients. Transplantation 1998; 65: 1506.
8. Lehtonen SRK, Taskinen EI, Isoniemi HM. Histological alterations in implant and one-year protocol biopsy specimens of renal allografts. Transplantation 2001; 72: 1138.
9. Mohamed MAS, Robertson H, Booth TA, Balupuri S, Kirby JA, Talbot D. TGF-β1 expression in renal transplant biopsies. Transplantation 2000; 69: 1002.
10. Ochsner S, Guo Z, Binswanger U, Knoflach A. TGF-β1 expression in stable renal transplant recipients: influence of TGF-β1 gene polymorphism and immunosuppression. Am J Transplant 2002; 2(Suppl. 3): 234 (Abstract).
11. Mohamed MAS, Burt AD, Robertson H, Kirby JA, Talbot D. TGF-β1 expression in protocol transplant liver biopsies: a comparative study between cyclosporine-A (CyA) and tacrolimus (FK506) immunosuppression. Transplant Proc 2001; 33: 1378.
12. Ahsan N, Johnson C, Gonwa T, et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after kidney transplantation: results at 2 years. Transplantation 2001; 72: 245.
13. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977.
14. Claesson K, Mayer AD, Squifflet J-P, et al, Lipoprotein patterns in renal transplant patients: a comparison between FK-506 and cyclosporine-A patients. Transplant Proc 1998; 30: 1292.
15. Margreiter R and European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with cyclosporin microemulsion in renal transplantation: a randomized multicentre study. Lancet 2002; 359: 741.
16. Hamar P, Muller V, Kohnle M, et al. Metabolic factors have a major impact on kidney allograft survival. Transplantation 1997; 64: 1135.